Results 31 to 40 of about 5,186 (110)

Association of Metabolic Genotype Composite CYP3A5*3 and CYP3A4*1B to Tacrolimus Pharmacokinetics in Stable Black and White Kidney Transplant Recipients

Clinical and Translational Science, Volume 18, Issue 10, October 2025.
ABSTRACT Interpatient variability in tacrolimus pharmacokinetics is due in part to variation in metabolism by cytochrome P‐450 3A5 and 3A4 and membrane transport by P‐glycoprotein. We evaluated the combined role CYP3A5*3 and CYP3A4*1B genotypes have on tacrolimus pharmacokinetics in 65 stable Black and White kidney transplant recipients receiving ...
Daniel Brazeau, Kristopher Attwood, Louse M. Cooper, Vanessa Gray, Shirley Chang, Shirley Chen, Brian M. Murray, Kathleen M. Tornatore   +7 more
wiley   +1 more source

Effect of Piperine Pretreatment on Biochemical Profiles of Acetaminophen-Induced Hepatotoxicity in Rats

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2012
BACKGROUND AND OBJECTIVE: Acetaminophen overdose is the most frequent cause of liver injuries. N-acetyl-p-benzoquinone imine (NAPQI) has been proposed as the toxic metabolite of acetaminophen induced by cytochrome P-450.
MT Kazemi, M Pour Nasrollah, MM Rezaei,, GH.A Jorsaraei, GH Maliji, S Kazemi, E Zabihi,, M Pouramir,, AA Moghadamnia   +8 more
doaj  

Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time

European Journal of Clinical Pharmacology, 2022
Tung, Norint P., Ma, Joseph D.
openaire   +2 more sources

Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study

Clinical Pharmacology in Drug Development, Volume 14, Issue 8, Page 631-641, August 2025.
Abstract Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T‐cell lymphoma and adult T‐cell leukemia/lymphoma. This Phase I, open‐label study evaluated the pharmacokinetics and safety of a single 50‐mg oral dose of valemetostat in
Masaya Tachibana, Thuy Vu Craveiro, Thomas C. Marbury, Samuel Oberstein, George J. Atiee, Ben Tao, Takako Shimizu, Yvonne Lau, Malaz A. Abutarif   +8 more
wiley   +1 more source

Response to: “Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time”

European Journal of Clinical Pharmacology, 2022
Kvitne, Kine Eide, Hole, Kristine, Molden, Espen, Robertsen, Ida   +3 more
openaire   +2 more sources

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Candidate-gene-based study of CYP3A-related single-nucleotide polymorphisms using 4β-hydroxycholesterol/cholesterol ratio as biomarker in a Japanese cohort. [PDF]

Eur J Clin Pharmacol
Tanaka R, Suzuki Y, Koyama T, Sumimoto T, Oda A, Sato H, Ozaki E, Tatsuta R, Yamamoto Y, Nakatochi M, Momozawa Y, Ohno K, Takashima N, Matsuo K, Itoh H.   +14 more
europepmc   +1 more source

Drug Interactions of Vebreltinib, a Novel Type I c-Met Inhibitor, Coadministration With Rifampin or Itraconazole in Healthy Participants. [PDF]

Clin Transl Sci
Chen J, Wu J, Song Y, Li J, Li L, Li L, Kong Y, Wu X, Yin H, Hou M, Wang B, Gao Q, Li R, Wu L, Xue W, Dong R.   +15 more
europepmc   +1 more source

Population Pharmacokinetic Model Assessment of the Effects of Body Weight on Risk of Drug-Drug Interactions After Posaconazole Discontinuation. [PDF]

Clin Transl Sci
Wrishko RE, Bateman TJ, Johnson MG, Kothare PA.   +3 more
europepmc   +1 more source

Comments to the Article Wu Y, Völler S, Goulooze SC, et al. A Novel Maturation Equation for Hepatic Clearance Across Preterm, Term Neonates, Children, and Adults: Application to Paracetamol and Its Metabolite. J Clin Pharmacol. 2025;65(12):1829-1843. doi: 10.1002/jcph.70080. PMID: 40910464; PMCID: PMC12649303. [PDF]

J Clin Pharmacol
Pasanen M, Juvonen RO.
europepmc   +1 more source